Cancers | Free Full-Text | Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program | Oncotarget
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - ScienceDirect
Potent treatment options in ALK– and MET-positive disease - memoinOncology
EGFR- and ALK-targeted treatment: present and future - memoinOncology
Stephen V Liu, MD on Twitter: "#ESMOAsia22 Survival is favoring alectinib for #ALK NSCLC over crizotinib, but not yet significant. Medians not reached and OS HR 0.60 overall with OS HR 0.40
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer - ScienceDirect
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program | Oncotarget
Kaplan-Meier analyses of survival in patients treated with alectinib... | Download Scientific Diagram
Diagnostics | Free Full-Text | Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib
A) Kaplan-Meier curve of progression-free survival (PFS) in the... | Download Scientific Diagram
Kaplan-Meier curve for overall survival after total follow-up of ALK+... | Download Scientific Diagram
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer☆ - ESMO Open
Progression-free survival by IRC Shown is the Kaplan-Meier curve for... | Download Scientific Diagram
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer - ScienceDirect
Natural History and Factors Associated with Overall Survival in Stage IV ALK‐Rearranged Non–Small Cell Lung Cancer | Semantic Scholar
Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence - Wang - 2022 - Cancer Medicine - Wiley Online Library
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer | SpringerLink
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Charu Aggarwal, MD, MPH on Twitter: "Final OS analysis of J-ALEX Alectinib vs Crizotinib ✴️ No significant OS difference BUT ✴️ Majority of patients crossed over to alectinib (~78%) @ALKLungCancer @alk_fusion @ASCO #
First-Line PFS - ALECENSA® (alectinib)
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer
First-Line PFS - ALECENSA® (alectinib)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - Annals of Oncology
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study — ALK POSITIVE
